EJHaem. 2026 Nov 14;7(6):e70451. doi: 10.1002/jha2.70451. eCollection 2026 Dec.
ABSTRACT
INTRODUCTION: Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia.
METHODS: We retrospectively evaluated 679 zanubrutinib-treated patients across 52 Italian centers, with 354 historical ibrutinib-treated controls. Shanafelt AF scores were assessed.
RESULTS: Nine zanubrutinib-treated patients developed AF (1.33%) during median treatment of 15.5 months, versus 42 historical controls (11.9%) over median observation of 25 months. Five zanubrutinib events occurred among patients scoring ≥ 5. No affected patients experienced embolic or bleeding complications.
CONCLUSION: AF was uncommon during zanubrutinib treatment, even in the higher-risk subgroup. Historical comparisons remain limited, and exploratory score findings require confirmation with longer follow-up.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.
PMID:43034813 | PMC:PMC13769379 | DOI:10.1002/jha2.70451